Signia Therapeutics is an innovative French start-up from the VirPath laboratory of the University Claude Bernard (Lyon).
SIGNIA Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.
Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with proofs-of-concept already established for several market-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications.
Learn moreTo identify and repurpose rapidly, efficiently and at low cost already marketed drugs for new antiviral indication
By targeting host cellular pathways instead of viral proteins, Signia therapeutics drug candidates achieve broad-spectrum antiviral efficacy and minimize the risk of emergence of drug-resistant viruses
Signia Therapeutics approach offers intrinsic de-risking of drug discovery process, with significant cost and time reduction to validate drug candidates, with rapid transition to phase 2 clinical evaluation.
Our research strategy is based on the direct exploitation of clinical samples and the characterisation of relevant in vivo transcriptomic signatures of infections, in an innovative bedside-to-bench and bench-to-bedside approach.
Acute respiratory tract infections (ARTI) represent the main cause of acute diseases worldwide and remain the number one cause of deaths in newborns and young children (nearly 2 million deaths/year). Respiratory pathogens constitute a major public health issue and represent a large socio-economic impact.
Up to now, very few efficient vaccines or antiviral candidate treatments have been reported in the medical literature to widely fight against these respiratory pathogens, except for those available against influenza viruses. In an effort to treat these various ARTIs, consumers spend more than $2-3 billion each year, yet new efficient antiviral strategies, less prone to the emergence of resistance, are necessary.
Learn moreLatest developments of Signia Therapeutics
Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with proofs-of-concept for several FDA-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications.
Creation of Signia Therapeutics
Signia therapeutics laureate of i-Lab 2017 Award
Entry of new Shareholders
Start of FluNext Phase 2 clinical assay
Major Licence agreement for three patents
EU H2020 seal of Excellence Award
Latest news about Signia Therapeutics - Press releases - Medias
Signia Therapeutics drug discovery platform has already demonstrated its significant potential with proofs-of- conc ...
LYON, FRANCE (May 27, 2020) - Signia Therapeutics announced today that it has received a grant of € 2.38 millionfrom the E ...
SIGNIA THERAPEUTICS will be in San Francisco fo ...
Do not hesitate to contact us!
Signia therapeutics.com - Copyright 2018. All right reserved.